Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics Inc (NQ: CADL )

7.830 +0.070 (+0.90%)
Streaming Delayed Price Updated: 2:09 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 366,778
Open 8.000
Bid (Size) 7.760 (4)
Ask (Size) 7.830 (1)
Prev. Close 7.760
Today's Range 7.680 - 8.330
52wk Range 0.6600 - 14.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Candel Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+440.00%
+440.00%
1 Month
+49.14%
+49.14%
3 Month
+30.94%
+30.94%
6 Month
+422.00%
+422.00%
1 Year
+552.50%
+552.50%

More News

Read More
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Via Benzinga
Looking Into Candel Therapeutics's Recent Short Interest
Via Benzinga
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Via News Direct
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
Why BioRestorative Therapies Stock Is Moving Higher Thursday
Via Benzinga
Candel Therapeutics to Join Russell 3000® Index
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
Via News Direct
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Via TheNewswire.com
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Via News Direct
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
Via InvestorPlace
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.